Welcome!

News Feed Item

Pediapharm Announces Fourth Quarter Results

MONTREAL, QUEBEC -- (Marketwired) -- 02/28/14 --

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Pediapharm Inc. (the "Corporation") (TSX VENTURE:PDP) is pleased to announce the filing of its fourth quarter financial results ended December 31, 2013. As a result of the Corporation changing its financial year-end from December 31 to March 31, these are interim financial statements. All dollars amount are expressed in Canadian currency and results are reported in accordance with IFRS accounting principles. Pediapharm reports the following highlights:

--  Total revenues for the twelve-month period ended December 31, 2013
    increased by 61% compared to the same period in 2012, which includes a
    fourth quarter increase of 117% compared to same period in 2012;

--  Operating loss for the twelve-month period ended December 31, 2013
    decreased by $1,639,805 compared to the same period in 2012, which
    includes a fourth quarter decrease of $506,436 compared to same period
    in 2012;

--  On December 27, 2013, the common shares of Pediapharm began to trade on
    the TSX Venture Exchange under the ticker symbol PDP.V following an
    amalgamation transaction with Chelsea Acquisition Corporation; 

--  Concurrently, the Corporation successfully completed a round of
    financing with gross proceeds of approximately $7,000,000; and

--  NYDA®, a breakthrough treatment for head lice and its eggs, was a
    major contributor to the revenue growth.

Total revenues for the 3 month-period ended December 31, 2013 increased by 117% to reach $1,237,538 compared to $570,945 in the same period in 2012. NYDA's strong performance in the last quarter, which coincides with one of the 3 peak seasons for head lice infestation, was an important factor contributing to the growth. On October 30, 2013, Pediapharm received the acceptance of NYDA's reimbursement by the Ontario Drug Benefit (ODB), enabling more patients to have access to the product when prescribed.

Total revenues for the twelve-month period ended December 31, 2013 increased to $4,003,807 (2012 - $2,490,503), representing a 61% increase compared to the same period in 2012. The solid performance of NYDA, the addition of Allerject(TM) in the Corporation's detailing portfolio and the strong performance of Suprax® were the main drivers of the increase in revenues.

The operating loss for the three months ended December 31, 2013 was $52,378 compared to the $558,814 in the three months ended December 31, 2012. The improvement was due to an increase in revenue of 117% as well as solid control of operating expenses. The net loss for the three months ended December 31, 2013 was $1,703,124 compared to the $659,958 in the three months ended December 31, 2012. The expenses related to the amalgamation with Chelsea Acquisition Corporation were the main reason for the difference in net loss.

The operating loss for the twelve months ended December 31, 2013 was $440,164 compared to the $2,079,969 in the twelve months ended December 31, 2012. The improvement was due to an increase in revenue of 61% as well as solid control of operating expenses. The net loss for the twelve months ended December 31, 2013 was $2,513,191 compared to the $2,246,068 in the twelve months ended December 31, 2012. The expenses related to the amalgamation with Chelsea Acquisition Corporation had an important impact on the 2013 net loss.

"2013 was an excellent year for Pediapharm. Following the amalgamation with Chelsea Acquisition Corporation and the concurrent financing with gross proceeds of approximately $7,000,000, the common shares of Pediapharm began to trade on the TSX Venture Exchange in December." stated Sylvain Chretien, President and Chief Executive Officer of Pediapharm. He added: "What is remarkable is that, even with the additional efforts required to complete the transaction, the Pediapharm team stayed very focused and achieved revenue growth of 61% while keeping the operating expenses similar to last year."

----------------------------------------------------------------------------
                            December     December     December     December 
                            31, 2013     31, 2012     31, 2013     31, 2012 
                          (3 months)   (3 months)  (12 months)  (12 months) 
----------------------------------------------------------------------------
Revenue                    1,237,538      570,945    4,003,807    2,490,503 
----------------------------------------------------------------------------
Selling and                                                                 
 administrative expenses   1,289,916    1,129,759    4,443,971    4,570,472 
----------------------------------------------------------------------------
Operating loss               (52,378)    (558,814)    (440,164)  (2,079,969)
----------------------------------------------------------------------------
Other expenses             1,650,746      101,144    2,073,027      166,099 
----------------------------------------------------------------------------
Net loss                  (1,703,124)    (659,958)  (2,513,191)  (2,246,068)
----------------------------------------------------------------------------
Cash flow from (used in)                                                    
 operating activities     (1,020,399)    (233,623)  (1,583,500)  (1,932,622)
----------------------------------------------------------------------------
Cash flow from (used in)                                                    
 investing activities        249,443          605      (61,789)     (78,372)
----------------------------------------------------------------------------
Cash flow from (used in)                                                    
 financing activities      6,375,730      286,284    7,157,548    1,804,644 
----------------------------------------------------------------------------

About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company's innovative product portfolio includes NYDA®; a breakthrough treatment for head lice; EpiCeram® a non-steroid emulsion for eczema; KoolEffect(TM) which reduces the symptoms of fever; and VapoLyptus(TM); a soothing vapour patch of Eucalyptus and Camphor.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD LOOKING STATEMENTS

This news release contains forward-looking statements and other statements that are not historical. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to vary materially from target results and the results or events predicted in these forward-looking statements. As a result, investors are cautioned not to place undue reliance on these forward-looking statements.

The forward-looking statements contained in this news release are made as of the date of this release. Except as required by applicable law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking information reflects the current expectations or belief of the Corporation based on information currently available and such information is subject to a number of assumptions, risks and uncertainties described in details at pp. 35 to 41 of the Management Information Circular of Chelsea Acquisition Corporation dated November 12, 2013 available on SEDAR at www.sedar.com and other risks associated with being a specialty pharmaceutical company.

Contacts:
Sylvain Chretien
President and Chief Executive Officer
Pediapharm Inc.
514-762-2626 ext. 201
[email protected]

Roland Boivin
Chief Financial Officer
Pediapharm Inc.
514-762-2626 ext. 202
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, discussed how by using ne...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
"NetApp is known as a data management leader but we do a lot more than just data management on-prem with the data centers of our customers. We're also big in the hybrid cloud," explained Wes Talbert, Principal Architect at NetApp, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...